AlzeCure Pharma AB (publ)
Stockholm Stock Exchange ALZCUR.ST
AlzeCure Pharma AB (publ) Price to Book Ratio (P/B) on January 14, 2025
-
AlzeCure Pharma AB (publ) 52-week high Price to Book Ratio (P/B) is NA on January 14, 2025, which is NA below the current Price to Book Ratio (P/B).
-
AlzeCure Pharma AB (publ) 52-week low Price to Book Ratio (P/B) is NA on January 14, 2025, which is NA below the current Price to Book Ratio (P/B).
-
AlzeCure Pharma AB (publ) average Price to Book Ratio (P/B) for the last 52 weeks is NA.
| Date | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield | Price to Earnings Ratio (P/E) |
|---|
| CEO | Mr. Martin Jönsson |
| IPO Date | Nov. 28, 2018 |
| Location | Sweden |
| Headquarters | HAelsovAegen 7 |
| Employees | 11 |
| Sector | Health Care |
| Industries | |
AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is developing drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its pipeline drug candidates include ACD856, which is in phase I clinical trial for Alzheimer's disease, sleep disorders, traumatic brain injuries, and Parkinson's disease; ACD857, ACD679, and ACD680 for Alzheimer's disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain; and TrkA-NAM for osteoarthritic pain. The company was founded in 2012 and is based in Huddinge, Sweden.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email